StocksMedium•4 November 2026•
1 min read
Nuvectis Pharma Reports $30.1 Million Q3 Net Loss and Expands Drug Pipeline
Key Facts
1Nuvectis Pharma reported a net loss of $30.1 million for the third quarter of 2026.
2The company announced the in-licensing of ex-China rights for two drug candidates.
Nuvectis Pharma reported a net loss of $30.1 million for the third quarter of 2026. Benzinga reported that the company also announced the in-licensing of ex-China rights for two new drug candidates as part of its quarterly financial and operational update.
NVCT closed at $19.34 on November 3, 2026, with the stock trading between a day low of $18.82 and a day high of $19.83 during that session. These financial results coincide with the company's efforts to expand its clinical pipeline through new licensing agreements.